Casdin discloses 9.7% BioLife Solutions stake (NASDAQ: BLFS)

Rhea-AI Filing Summary

BioLife Solutions, Inc. investor Casdin Capital and affiliates report a 9.7% beneficial ownership stake, or 4,757,165 common shares. This percentage is based on 48,857,415 shares outstanding as of April 30, 2026. The stake is held through Casdin Partners Master Fund, L.P., its general partner, and Eli Casdin.

The shares were acquired for investment using the fund’s working capital, without specific borrowing for this position. The group states it currently has no concrete plans for corporate changes but may engage with management, directors, and other shareholders on alternatives to maximize shareholder value and could adjust its holdings over time.

Insights

Equity ownership and activism analyst

Casdin reports a 9.7% BioLife stake with flexible engagement language.

Casdin Capital and related entities disclose beneficial ownership of 4,757,165 BioLife Solutions shares, or 9.7% of the common stock based on 48,857,415 shares outstanding as of April 30, 2026. The position is held for investment, funded from the master fund’s working capital.

The filing states no current plans for transactions such as mergers, board changes, or recapitalizations, yet explicitly reserves the right to pursue such actions later. It also notes ongoing and potential dialogue with management, directors and other shareholders about alternatives to maximize shareholder value.

This combination of a near-10% position and open-ended language is typical of investors who want latitude to become more active if circumstances change. Actual impact will depend on any future proposals or trading activity described in subsequent company or investor filings.

Key Figures

Beneficial ownership: 4,757,165 shares Ownership percentage: 9.7% Shares outstanding: 48,857,415 shares +3 more

6 metrics

Beneficial ownership 4,757,165 shares BioLife Solutions common stock held by Casdin group

Ownership percentage 9.7% Portion of BioLife Solutions common shares owned

Shares outstanding 48,857,415 shares BioLife Solutions shares outstanding as of April 30, 2026

Sole voting power 0 shares Casdin and affiliates’ sole voting authority

Shared voting power 4,757,165 shares Casdin and affiliates’ shared voting authority

Event date 05/20/2026 Date of event triggering Schedule 13D/A amendment

Key Terms

beneficial owners, Schedule 13D, dispositive power, working capital, +1 more

5 terms

beneficial owners financial

"may be deemed to be the beneficial owners of 4,757,165 Shares"

Beneficial owners are the people or entities that actually enjoy the economic benefits and control of shares or other assets, even when legal title is held by someone else such as a broker, custodian or trustee. Investors pay attention because beneficial owners hold the real voting power, receive dividends and can influence strategy and takeover outcomes — like the driver of a car who uses and maintains it while the bank holds the title — so disclosure shows who truly controls and benefits.

Schedule 13D regulatory

"previously filed a statement on Schedule 13G to report the acquisition"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

dispositive power financial

"has the shared power to dispose or direct the disposition of 4,757,165 Shares"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

working capital financial

"came from the working capital of the Fund, over which the Reporting Persons"

Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.

extraordinary corporate transaction regulatory

"which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate transaction"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

BIOLIFE SOLUTIONS INC

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

09062W204

(CUSIP Number)

Eli Casdin
Casdin Capital, LLC, 1350 Avenue of the Americas, Suite 2600
New York, NY, 10019
212) 897-5438

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/20/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 09062W204

1

Name of reporting person

Casdin Capital, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4,757,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4,757,165.00

11

Aggregate amount beneficially owned by each reporting person

4,757,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.7 %

14

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13D

CUSIP Number(s): 09062W204

1

Name of reporting person

Casdin Partners Master Fund, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4,757,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4,757,165.00

11

Aggregate amount beneficially owned by each reporting person

4,757,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.7 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 09062W204

1

Name of reporting person

Casdin Partners GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4,757,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4,757,165.00

11

Aggregate amount beneficially owned by each reporting person

4,757,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.7 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 09062W204

1

Name of reporting person

Eli Casdin

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4,757,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4,757,165.00

11

Aggregate amount beneficially owned by each reporting person

4,757,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.7 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: BIOLIFE SOLUTIONS INC
(c)	Address of Issuer's Principal Executive Offices: 3303 Monte Villa Parkway, Suite 310, Bothell, WASHINGTON , 98021.
Item 1 Comment: The name of the issuer is BioLife Solutions, Inc., a Delaware corporation (the "Issuer"). The address of the Issuer's principal executive offices is 3303 Monte Villa Parkway, Suite 310, Bothell, Washington, 98021. This Schedule 13D amendment relates to the Issuer's Common Stock, par value $0.001 per share (the "Shares").
Item 2.	Identity and Background
(a)	This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company ("Casdin"), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), Casdin Partners GP, LLC, a Delaware limited liability company (the "GP") and Eli Casdin, a United States citizen (collectively, the "Reporting Persons").
(b)	The principal business address for each of the Reporting Persons is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019.
(c)	Eli Casdin is the managing member of Casdin and the GP. The principal business of Casdin is serving as an investment adviser to its clients. The principal business of the GP is serving as the general partner to certain private funds. Casdin is the investment manager to the Fund and the GP is the general partner of the Fund. The principal business of the Fund is purchasing, holding and selling securities for investment purposes.
(d)	During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Persons disclaim membership in a group.
Item 3.	Source and Amount of Funds or Other Consideration
	The funds for the purchase of the Shares by the Fund came from the working capital of the Fund, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion. No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.
Item 4.	Purpose of Transaction
	The Reporting Persons have acquired their Shares of the Issuer for investment. The Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate transaction involving the Issuer; (b) any change in the present Board of Directors or management of the Issuer; (c) any material change in the present capitalization or dividend policy of the Issuer; (d) any material change in the operating policies or corporate structure of the Issuer; (e) any change in the Issuer's charter or by-laws; (f) the Shares of the Issuer ceasing to be listed from a national securities exchange or to ceasing to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; or (g) causing the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934. The Reporting Persons, however, reserve the right, at a later date, to effect one or more of such changes and may dispose of or enter into other transactions in the shares they may be deemed to beneficially own. The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value. The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should it determine to do so, and/or to recommend courses of action to management and the shareholders of the Issuer.
Item 5.	Interest in Securities of the Issuer
(a)	As of the date hereof, Casdin, the Fund, the GP and Eli Casdin may be deemed to be the beneficial owners of 4,757,165 Shares, constituting 9.7% of the Shares based upon 48,857,415* Shares outstanding. Casdin has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 4,757,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 4,757,165 Shares. The Fund has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 4,757,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 4,757,165 Shares. The GP has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 4,757,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 4,757,165 Shares. Eli Casdin has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 4,757,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 4,757,165 Shares. The transactions by the Reporting Persons in the Shares are set forth in Exhibit B. *This outstanding Shares figure reflects the number of outstanding Shares as of April 30, 2026.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not Applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit A: Joint Filing Agreement Exhibit B: Schedule of Transactions in Shares

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Casdin Capital, LLC

Signature:	/s/ Eli Casdin
Name/Title:	Eli Casdin, Managing Member
Date:	05/22/2026

Casdin Partners Master Fund, L.P.

Signature:	/s/ Eli Casdin
Name/Title:	Eli Casdin, Managing Member of its General Partner
Date:	05/22/2026

Casdin Partners GP, LLC

Signature:	/s/ Eli Casdin
Name/Title:	Eli Casdin, Managing Member
Date:	05/22/2026

Eli Casdin

Signature:	/s/ Eli Casdin
Name/Title:	By Eli Casdin
Date:	05/22/2026

Comments accompanying signature:

These reporting persons disclaim beneficial ownership of these reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose.

FAQ

How many BioLife Solutions (BLFS) shares does Casdin Capital beneficially own?

Casdin Capital and related entities beneficially own 4,757,165 BioLife Solutions shares. This represents a significant single-holder position and reflects shares held through Casdin Partners Master Fund, its general partner, and Eli Casdin acting together as reporting persons.

What percentage of BioLife Solutions (BLFS) is owned by Casdin according to this Schedule 13D/A?

Casdin reports beneficial ownership of 9.7% of BioLife Solutions’ common stock. This percentage is calculated using 48,857,415 shares outstanding as of April 30, 2026, giving Casdin meaningful influence without crossing typical 10% regulatory thresholds.

How did Casdin fund its BioLife Solutions (BLFS) share purchases?

The BioLife Solutions shares were purchased using the working capital of Casdin Partners Master Fund. The filing specifies that no special borrowing was used, other than ordinary-course borrowing for working capital needs across the fund’s broader investment activities.

Does Casdin have activist plans for BioLife Solutions (BLFS)?

Casdin states it currently has no specific plans for transactions like mergers, board changes, or recapitalizations. However, the group reserves the right to pursue such actions later and has been in contact with management and other shareholders about ways to maximize shareholder value.

What voting and dispositive power does Casdin have over BioLife Solutions (BLFS) shares?

Casdin and the related reporting entities report shared voting and shared dispositive power over 4,757,165 BioLife Solutions shares, and no sole voting or sole dispositive power. This means decisions over these shares are exercised jointly under their investment structure.

Why did Casdin file an amended Schedule 13D/A for BioLife Solutions (BLFS)?

The amended Schedule 13D/A updates Casdin’s beneficial ownership details in BioLife Solutions, reflecting a 9.7% position and current intentions. It also clarifies the organizational structure, funding source for the investment, and the group’s reserved flexibility to engage on strategic alternatives.